UroGen Pharma URGN Accrued Financing On Prepaid Forward Obligation
Accrued Financing On Prepaid Forward Obligation at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept urgn:AccruedFinancingOnPrepaidForwardObligation.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's accrued financing on prepaid forward obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's accrued financing on prepaid forward obligation?
- UroGen Pharma (URGN) reported accrued financing on prepaid forward obligation of $1.06M in Q1 2026.
- How has UroGen Pharma's accrued financing on prepaid forward obligation changed year-over-year?
- UroGen Pharma's accrued financing on prepaid forward obligation increased by 156.1% year-over-year, from -$1.89M to $1.06M.
- What is the long-term trend for UroGen Pharma's accrued financing on prepaid forward obligation?
- Over 4 years (2021 to 2025), UroGen Pharma's accrued financing on prepaid forward obligation has grown at a -33.7% compound annual growth rate (CAGR), from $14.85M to $2.87M.
- What does accrued financing on prepaid forward obligation mean?
- Represents the non-cash accrual of financing costs associated with prepaid forward contracts or similar structured financing arrangements. This metric tracks the periodic expense recognition of obligations that have been settled in advance, impacting the company's overall cost of capital.